Codexis Advances ECO Synthesis Toward Adoption Readiness with Quality at Scale and Expanded siRNA Manufacturing Capabilities

Codexis shows >90% quality and faster production for siRNA at 100-gram scale.

What the company is saying

Codexis is highlighting new technical data for its ECO Synthesis Manufacturing Platform, emphasizing product quality above 90% and nearly halved cycle time at the 100-gram scale. The company claims this high performance is consistent across three orders of magnitude in scale, suggesting robust scalability. Management, including President and CEO Alison Moore and Chief Scientific Officer Stefan Lutz, frame the platform as advancing toward industrialization and enabling molecular precision for next-generation RNA therapeutics. The announcement stresses expanded capabilities, such as efficient incorporation of tissue-targeting moieties and control of phosphorothioate stereochemistry, as differentiators for siRNA manufacturing. Codexis also reports a 3- to 4-fold increase in potency for siRNA produced with ECO Synthesis in human hepatocyte in vitro models compared to traditional chemical synthesis. The tone is confident and forward-leaning, positioning the platform as ready for broader adoption but without disclosing commercial contracts or financial outcomes.

What the data suggests

The disclosed data confirm that Codexis achieved product quality above 90% at the 100-gram manufacturing scale, with nearly half the cycle time compared to previous processes. This level of performance was reportedly maintained across three orders of magnitude in scale, supporting claims of scalability. The company presents biological evidence of a 3- to 4-fold increase in potency for siRNA produced using its enzymatic platform in human hepatocyte in vitro models, compared to chemically synthesized equivalents. While these technical results are specific and credible, the announcement does not provide financial metrics, commercial adoption rates, or quantified cost savings. Several claims, such as efficient incorporation of tissue-targeting moieties and reduced capital requirements, are not supported by numerical data. The evidence base is strong for technical performance but incomplete for commercial or financial impact.

Analysis

The announcement presents a positive tone, highlighting technical achievements such as >90% product quality at 100-gram scale, halved cycle time, and a 3- to 4-fold potency increase in vitro. These realised metrics are credible and supported by disclosed data. However, a significant portion of the narrative is forward-looking, emphasizing ongoing process improvements, industrialization, and potential future benefits (e.g., lower capital requirements, greater efficiency, and reduced costs) without providing financial or commercial adoption data. The claims about platform readiness, scalability, and broad manufacturing impact are aspirational and not yet substantiated by commercial milestones or profitability metrics. No large capital outlay is disclosed, and the benefits are positioned as long-term, with no immediate financial impact. The gap between technical progress and commercial or financial outcomes is notable, and the language inflates the platform's near-term significance relative to the evidence.

Risk flags

• ●There is a significant gap between technical progress and commercial adoption, as no manufacturing contracts, revenue figures, or customer commitments are disclosed. This raises uncertainty about the platform's near-term monetization.
• ●The announcement relies heavily on forward-looking statements about industrialization and efficiency gains without providing concrete milestones or financial projections. This pattern increases the risk that anticipated benefits may be delayed or not materialize.
• ●Claims of expanded capabilities, such as tissue-targeting and stereochemical control, are not backed by quantitative data or third-party validation, introducing risk around the real-world impact and differentiation of these features.

Bottom line

Codexis has demonstrated strong technical progress with its ECO Synthesis platform, achieving over 90% product quality and faster cycle times at a meaningful 100-gram scale, and showing a 3- to 4-fold potency increase in vitro for siRNA. These results suggest the platform is technically robust and potentially scalable. However, the absence of commercial contracts, revenue figures, or concrete adoption milestones means the financial impact is still speculative. The company's narrative is credible on technical grounds but aspirational regarding market readiness and economic value. Investors should focus on evidence of commercial uptake, such as signed manufacturing deals or revenue disclosures, to gauge when and if these technical advances will translate into financial returns. The most important takeaway is that while Codexis's technology is advancing, the path to monetization and widespread adoption is still unproven.

Announcement summary

(NASDAQ:CDXS) Codexis, Inc. presented new data at TIDES Europe 2026 highlighting the quality, stereo-control, and manufacturing performance of its ECO Synthesis® Manufacturing Platform. The company demonstrated product quality above 90% at the 100-gram scale, while nearly halving cycle time compared to previous processes. This high level of performance was maintained consistently across three orders of magnitude in scale. Codexis also showcased new ECO Synthesis capabilities that support optimal siRNA design and manufacturing, including efficient incorporation of tissue-targeting moieties, which are important for siRNA therapeutics. The company provided an initial readout from an ongoing structure-activity relationship (SAR) study, sharing biological data for siRNA therapeutics with defined phosphorothioate stereochemistry. Material produced using the scalable ECO Synthesis platform showed a 3- to 4-fold increase in potency in human hepatocyte in vitro models compared to identical siRNA synthesized using traditional chemical methods. Alison Moore, President and CEO of Codexis, stated that the data demonstrate the quality and manufacturing performance of ECO Synthesis at 100-gram scale, and that ongoing process improvements are increasing productivity as the platform advances toward industrialization. Stefan Lutz, Ph.D., Chief Scientific Officer of Codexis, emphasized the importance of molecular precision enabled by enzymatic synthesis, including the ability to incorporate targeting functionality and control phosphorothioate stereochemistry. The data presented at TIDES Europe demonstrate continued progress toward adoption readiness for ECO Synthesis as a manufacturing platform for siRNA therapeutics. The platform's quality and consistency at 100-gram scale, improving process productivity, and expanded capabilities for targeted delivery and stereochemical control highlight its growing potential for scalable, differentiated RNA manufacturing. Codexis is developing its proprietary ECO Synthesis® Manufacturing Platform as an aqueous enzymatic process that may offer a scalable alternative to traditional solid phase organic synthesis of oligonucleotide manufacturing. The company is initially applying this technology to address the growing demand for RNAi therapeutics. Codexis’ unique enzymes can drive improvements such as higher yields, increased purity, reduced energy usage and waste generation, stereoisomer control of siRNA, and improved overall capacity in manufacturing at substantially lower capital requirements, potentially leading to greater efficiency and reduced costs. Additionally, Codexis supplies high-performance enzymes through its BioCatalysis business for the manufacture of multiple commercially available small molecule therapeutics.

Disagree with this article?